Importantly, the IC score in the current study, which was adopted from the IMpassion130 trial [14], is the proportion of tumor area occupied by PD-L1-positive immune cells, different from the typical IHC interpretation where the denominator is the total number of cells. This evidence concerns the gene CD274 and neoplasm.